Potential savings in Medicaid antiseizure medication reimbursement, 2008-2025: persistent brand-name reimbursement despite generic availability.
- DOI
- 10.1080/14737167.2026.2757890
- Published
- 2026 Nov 2
- Container
- Expert review of pharmacoeconomics & outcomes research
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1080/14737167.2026.2757890,
title = {Potential savings in Medicaid antiseizure medication reimbursement, 2008-2025: persistent brand-name reimbursement despite generic availability.},
author = {Mtchedlidze T and Sah J and Modebadze G and Javarayee P},
year = {2026},
journal = {Expert review of pharmacoeconomics \& outcomes research},
doi = {10.1080/14737167.2026.2757890},
url = {https://doi.org/10.1080/14737167.2026.2757890}
}RIS
TY - JOUR TI - Potential savings in Medicaid antiseizure medication reimbursement, 2008-2025: persistent brand-name reimbursement despite generic availability. AU - Mtchedlidze T AU - Sah J AU - Modebadze G AU - Javarayee P PY - 2026 JO - Expert review of pharmacoeconomics & outcomes research DO - 10.1080/14737167.2026.2757890 UR - https://doi.org/10.1080/14737167.2026.2757890 ER -
APA
T, M., J, S., G, M., & P, J. (2026). Potential savings in Medicaid antiseizure medication reimbursement, 2008-2025: persistent brand-name reimbursement despite generic availability.. Expert review of pharmacoeconomics & outcomes research. https://doi.org/10.1080/14737167.2026.2757890
Source records
- pubmed · retrieved 2026-11-10T13:37:19.115Z